Triple immunotherapy cocktail tested in advanced cancers
NCT ID NCT04495257
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase study tested an experimental drug called APX005M added to two standard immunotherapies (nivolumab and ipilimumab) in 26 people with advanced melanoma or kidney cancer who had not received prior immune therapy. The main goals were to check safety and find the best dose. The study is complete, but results are not yet reported.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
APX005M (an experimental immune-boosting drug) combined with nivolumab and ipilimumab (two approved immunotherapy drugs)
What this could lead to
If this combination proves safe and effective, it could lead to a new treatment option for advanced melanoma and kidney cancer.
What could go wrong
This is a very early Phase 1 trial with only 26 participants, focused on safety and dosing. The combination may cause severe side effects, and it is too soon to know if it works better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Yale Cancer Center
New Haven, Connecticut, 06519, United States
-
Yale New Haven Hospital
New Haven, Connecticut, 06520, United States